quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The left and right agree on one thing: no data centers

View original at theverge.com
The Verge AI - Consumer Ai Title: The left and right agree on one thing: no data centers Date: 2026-08-06 14:00 Source: https://www.theverge.com/podcast/971855/ai-data-center-backlash-protests-florida-bipartisan <figure> <img alt="A photo illustration featuring data center protesters." src="https://platform.theverge.co…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Reframed campaign messaging around making Florida the financial capital of the world and emphasizing 'responsible development' while maintaining a pro-data center position, after facing voter backlash over data center support

    60% confidence

  • Understands that data centers are necessary but opposes construction of massive hyperscale facilities

    60% confidence

  • Public officials stated on video that they could not say whether they had signed a non-disclosure agreement regarding data center project details

    60% confidence

  • Anecdotal report that ChatGPT told a user they could not be friends with a specific person, cited as an example of AI products causing community fracturing and not winning hearts and minds

    60% confidence

  • Claimed one stillborn calf occurred near a data center; this single anecdote grew into a viral social media narrative about widespread cattle deaths near data centers

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The left and right agree on one thing: no data centers — Source | Via News | pt.VIA.NEWS